special report - blt, page-8

Mudpecker et al, I am interested in your views on these two latest blurbs.

I'm thinking there is a basic issue where PF is being forced to tell a long long story in a short short time. There is so much to tell and these people, who are supposed to spread the word, are starting to get confused.

I reckon a new approach is needed. It will be OK once we get efficacy or licence to Gradalis for phase three trials. By then it will be up to people to DYOR or miss the boat. Right now though, apart from calling for heads to roll, what do you think they should do about it.